Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose ...

BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today

Related Keywords

Boston ,Massachusetts ,United States ,Chicago ,Illinois ,American ,Michael Biega ,Shiraj Sen ,Sensei Biotherapeutics ,Joyce Allaire ,Exchange Commission ,American Society Of Clinical Oncology ,Nasdaq ,Sensei Biotherapeutics Inc ,Linkedin ,Clinical Oncology ,Annual Meeting ,Developmental Therapeutics ,Tumor Microenvironment Activated ,Immunoglobulin Domain Containing ,Private Securities Litigation Reform Act ,Annual Report ,Periodic Reports ,Region ,